FrancophonIA/ELRC3.0 huggingface dataset:
English: • heart problems or high blood pressure (e.g., amiodarone, quinidine, disopyramide, sotalol)
Maltese: • Problemi tal-qalb jew pressjoni għolja (eż., amiodarone, quinidine, disopyramide, sotalol)
English: • fungal infections (e.g. pentamidine)
Maltese: • Infezzjonijet fungali (eż. pentamidine)
English: Hydroxyzine is not recommended in elderly patients because of a decrease of hydroxyzine elimination in this population as compared to adults and the greater risk of adverse reactions (e.g. anticholinergic effects) (see sections 4.2 and 4.8).
Maltese: Hydroxyzine m'huwiex irrikkmandat f'pazjenti anzjani minħabba li jkun hemm tnaqqis taleliminazzjoni ta' hydroxyzine f'din il-popolazzjoni meta imqabbla ma' adulti u riskju akbar ta' reazzjonijiet avversi (eż. effetti antikolinergiċi) (ara sezzjonijiet 4.2 u 4.8).
English: The product information may be subsequently updated by the Member State competent authorities, in liaison with the Reference Member State, as appropriate, in accordance with the procedures laid down in Chapter 4 of Title III of Directive 2001/83/EC.
Maltese: It-tagħrif dwar il-prodott jista' sussegwentament jiġi aġġornat minn awtoritajjiet kompetenti talIstati Membri, flimkien ma Stat Membru ta' Referenza, bi qbil mal-proċeduri deskritti f' Kapitlu 4 ta' Titlu III ta' Direttiva 2001/83/EC.
English: In the elderly, the maximum daily dose is 50 mg per day (see section 4.4).
Maltese: Fl' anzjani, id-doża massima ta' kuljum hija ta' 50 mg kuljum (ara sezzjoni 4.4).
English: Associations contraindicated
Maltese: Assoċjazzjonijiet kontraindikati
English: Patients with a known risk factor to QT interval prolongation including a known cardiovascular disease, significant electrolytes imbalance (hypokalaemia, hypomagnesaemia), family history of sudden cardiac death, significant bradycardia, concomitant use with drugs known to prolong the QT interval and/or induce Torsade de Pointes (see sections 4.4 and 4.5).
Maltese: Pazjenti b' fattur ta' riskju magħruf ta' titwil fl-interval QT li jinkludi marda magħrufa wit kardjovaskulari, żbilanċ sinifikanti tal-electrolytes (ipokalimja, ipomagnesimja), storja fil-familja ta' mewt f'daqqa b' mard tal-qalb, bradikardja sinifikanti, l-użu flimkien b'mediċini li huma magħrufa li jtawlu l-interval QT u/jew induzzjoni ta' Torsade de Pointes (ara sezzjoni 4.4 u 4.5).
English: Therefore, the combination is contra-indicated (see section 4.3).
Maltese: Għaldaqstant it-teħid flimkien mhux irrakommandat (ara sezzjoni 4.3).
English: Hydroxyzine has been associated with prolongation of the QT interval on the electrocardiogram.
Maltese: Hydroxyzine kien assoċjat ma' titwil fl-intervall QT interval fuq l-elektrokardjogramma.
English: Hydroxyzine is metabolized by alcohol dehydrogenase and CYP3A4/5 and an increase in hydroxyzine blood concentrations may be expected when hydroxyzine is co-administered with drugs known to be potent inhibitors of these enzymes.
Maltese: Assoċjazzjonijiet li għandhom bżonn prekawzjonijiet għall-użu Hydroxyzine huwa metabolizzat minn alkoħol dehydrogenase u CYP3A4/5 u żieda f'konċentrazzjonijet ta' hydroxyzine fid-demm huma mistennija meta hydroxyzine jingħata flimkien ma' mediċini li huma magħrufa bħala inhibituri qawwija ta' dawn l-enżimi.
English: In adults and children over 40 kg in weight, the maximum daily dose is 100 mg per day.
Maltese: F' adulti u tfal b' piz ta' 40kg ‘l fuq, id-doża massima ta' kuljum hija ta' 100 mg kuljum.
English: In adults and children over 40 kg in weight, the maximum daily dose is 100 mg per day in all indications.
Maltese: F' adulti u tfal b' piz ta' 40kg ‘l fuq, id-doża massima ta' kuljum hija ta' 100 mg kuljum flindikazzjonijiet kollha.
English: In the elderly, the maximum daily dose is 50 mg per day.
Maltese: Fl' anzjani, id-doża massima ta' kuljum hija ta' 50 mg kuljum.
English: - if your ECG (electrocardiogram) shows a heart rhythm problem called “QT interval prolongation” - if you have or had a cardiovascular disease or if your heart rate is very low - if you have low salt levels in your body (e.g. low level of potassium or of magnesium) - if you are taking certain medicines for heart rhythm problems or medicines that may affect the heart rhythm (see “Other medicines and X”) - if anyone in your close family has died suddenly of heart problems
Maltese: - jekk għandek livelli tal-melħ fil-ġisem baxxi (eż. Livel baxx ta' potassju jew ta' magnizju) - jekk qed tieħu ċerti mediċini għal problemi ta' ritmu tal-qalb jew mediċini li jistgħu jaffetwaw ir ritmu tal-qalb (ara “Mediċini oħra u X”) - jekk xi ħadd fil-familja viċina miet f'daqqa b'problemi tal-qalb
English: Elderly patients
Maltese: Pazjenti anzjani
English: X can affect or be affected by other medicinal products.
Maltese: X jista' jaffetwa jew ikun affetwat minn prodotti mediċinali oħra.
English: An ECG monitoring could be undertaken, because of the possibility of a heart rhythm problem such as QT interval prolongation or Torsade de Pointes.
Maltese: Irid isir monitoraġġ tal-ECG, minħabba lpossibilta`ta' problemi ta' ritmu tal-qalb bħal titwil fl-intervall QT jew Torsade de Pointes.
English: Section 3 “How to <take> <use> X”
Maltese: Sezzjoni 2 “X'għandek tkun taf qabel ma <tieħu> <tuża> X”
English: Treatment with hydroxyzine should be stopped if signs or symptoms occur that may be associated with cardiac arrhythmia, and the patients should seek immediate medical attention.
Maltese: It-trattament b' hydroxyzine għandu jitwaqqaf jekk iseħħu sinjali jew sintomi li jistgħu jiġu assoċjati ma' arrythmias tal-qalb, u l-pazjenti għandhom jirrkorru għal kura medika immedjatament.
English: During post-marketing surveillance, there have been cases of QT interval prolongation and torsade de pointes in patients taking hydroxyzine.
Maltese: Waqt issorveljanza ta' wara t-tqegħid fis-suq, kien hemm każijiet ta' titwil fl-interval QT u torsade de pointes f'pazjenti li jieħdu hydroxyzine.
English: Patients with a known acquired or congenital QT interval prolongation.
Maltese: Tieħux X jekk qed tieħu mediċini biex titratta:
English: While taking X, seek immediate medical attention if you experience heart problems such as palpitations, trouble breathing, loss of consciousness.
Maltese: Waqt li qed tieħu X, fittex immedjatament attenzjoni medika jekk ikollok problemi tal-qalb bħal palpitazzjonijiet, diffikulta` biex tieħu nifs, jekk tintilef minn sensik.
English: • drug abuse or severe pain (methadone)
Maltese: • abbuż tad-droġa jew uġiegħ sever (methadone)
English: Caution with bradycardia and hypokalaemia-inducing drugs.
Maltese: Attenzjoni b'mediċini li jikkawżaw bradikardja u ipokalimja.
English: The marketing authorisation holders shall provide evidence in support of proportionate, feasible and effective measures to prevent the risk of overdose and minimise the risk of hepatic injury following intentional or accidental overdoses with modified release paracetamol containing products.
Maltese: Id-detenturi tal-awtorizzazzjoni għat-tqegħid fuq is-suq għandhom jipprovdu evidenza li tappoġġja attivitajiet proporzjonati, fattibbli u effettivi għall-prevenzjoni tar-riskju ta' doża eċċessiva u sabiex jiġi minimizzat ir-riskju ta' korriment epatiku wara dożi eċċessivi intenzjonati jew aċċidentali bi prodotti li fihom il-paracetamol li terħi l-mediċina b'mod modifikat.
English: For the suspension of products containing paracetamol, modified and prolonged to be lifted, the competent authorities shall ensure that the below conditions have been completed by the marketing authorisation holders.
Maltese: Sabiex titneħħa s-sospensjoni ta' prodotti li fihom il-paracetamol, li terħi l-mediċina b'mod modifikat u prolungat, l-awtoritajiet kompetenti għandhom jiżguraw li l-kundizzjonijiet t'hawn taħt ikunu ġew issodisfati mid-detenturi tal-awtorizzazzjoni għat-tqegħid fis-suq tal-komunità.
English: Conditions for lifting the suspension of the marketing authorisations
Maltese: Kundizzjonijiet għat-tneħħija tas-sospensjoni tal-awtorizzazzjonijiet għat tqegħid fis-suq tal-komunità
English: Strength Pharmaceutical Form Route of administration Packaging
Maltese: Għamla farmaċewtika
English: Invented name
Maltese: Numru ta' l-EU Isem ivvintat
English: EU number
Maltese: Qawwa
English: EU/1/13/872/001 EU/1/13/872/002
Maltese: EU/1/13/872/002
English: CCR5 Antagonists Maraviroc
Maltese: Antagonisti ta' CCR5 Maraviroc
English: ANTIRETROVIRALS
Maltese: ANTIRETROVIRALI
English: • HMG Co-A reductase inhibitors: lovastatin, simvastatin
Maltese: • impedituri ta' HMG Co-A reductase: lovastatin, simvastatin
English: Polyvinyl alcohol (partially hydrolysed) (E1203) Talc (E553B)
Maltese: Polyvinyl alcohol (parzjalment idrolizzat) (E1203) Talc (E553B)
English: • antimycobacterials: rifampicin
Maltese: • antimikobatteriċi: rifampicin
English: • ergot derivatives: dihydroergotamine, ergometrine, ergotamine
Maltese: • derivattivi ta' ergot: dihydroergotamine, ergometrine, ergotamine
English: • antiarrhythmics: amiodarone, quinidine
Maltese: • mediċini antiarritmiċi: amiodarone, quinidine
English: Week 144b
Maltese: Ġimgħa 144b
English: • alpha 1-adrenoreceptor antagonists: alfuzosin
Maltese: • antagonisti tal-adrenoriċettur alpha 1: alfuzosin
English: Systemic lidocaine Mexiletine
Maltese: Lidocaine sistemiku Mexiletine
English: PC: {number} SN: {number} NN: {number} [Outer packaging only]
Maltese: {numru} NN: {numru} [Pakkett ta' barra biss]
English: Sunset yellow FCF aluminium lake (E110), macrogol 3350 (E1521), polyvinyl alcohol (partially hydrolysed) (E1203), talc (E553B), titanium dioxide (E171), iron oxide yellow (E172) (see section 2 of this leaflet).
Maltese: Sunset yellow FCF aluminium lake (E110), macrogol 3350 (E1521), polyvinyl alcohol (parzjalment idrolizzat) (E1203), talc (E553B), titanium dioxide (E171), iron oxide yellow (E172) (ara sezzjoni 2 ta' dan il-fuljett).
English: Tablet core Croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicon dioxide.
Maltese: Croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicon dioxide.
English: Titanium dioxide (E171) Iron oxide yellow (E172)
Maltese: Titanium dioxide (E171)
English: HIV-1 RNA < 50 copies/ml Treatment difference -2.2% (95% CI = -7.4%, 3.0%) -2.1% (95% CI = -8.7%, 4.5%)
Maltese: Differenza fit-trattament -2,2% (95% CI = -7.4%, 3.0%) -2.1% (95% CI = -8.7%, 4.5%) Insuffiċjenza viroloġikac
English: See sections 4.2, 4.4, 5.1 and 5.2.
Maltese: Ara sezzjonijiet 4.2, 4.4, 5.1 u 5.2.
English: Table 2: Interactions between cobicistat and other medicinal products
Maltese: Tabella 2: Interazzjonijiet bejn cobicistat u prodotti mediċinali oħra
English: HMG Co-A REDUCTASE INHIBITORS Fluvastatin
Maltese: IMPEDITURI TA' HMG-COA REDUCTASE Fluvastatin
English: Buprenorphine/Naloxone
Maltese: Buprenorphine/Naloxone Buprenorphine:
English: Cobicistat inhibits the transporters P-gp, BCRP, MATE1, OATP1B1 and OATP1B3.
Maltese: Cobicistat jinibixxi t-trasportaturi ta' P-gp, BCRP, MATE1, OATP1B1 u OATP1B3.
English: The active substance is cobicistat.
Maltese: Is-sustanza attiva hi cobicistat.
English: NEUROLEPTICS Perphenazine Risperidone Thioridazine
Maltese: NEWROLETTIĊI Perphenazine Risperidone Thioridazine
English: Macrolide antibiotics Clarithromycin
Maltese: Antibijotiċi makrolidi Clarithromycin
English: • herbal products: St. John's wort (Hypericum perforatum)
Maltese: John's wort (Hypericum perforatum)
English: Recommended dose for adults:
Maltese: Doża rakkomandata għall-adulti:
English: • anticonvulsants: carbamazepine, phenobarbital, phenytoin
Maltese: • mediċini kontra l-konvulżjonijiet: carbamazepine, phenobarbital, phenytoin
English: • neuroleptics/antipsychotics: pimozide, lurasidone
Maltese: • mediċini newroleptiċi/antipsikotiċi: pimozide, lurasidone
English: Cmin: NC Ethinyloestradiol:
Maltese: Ethinyloestradiol:
English: PHOSPHODIESTERASE TYPE-5 (PDE-5) INHIBITORS Sildenafil
Maltese: TA' PHOSPHODIESTERASE TA' TIP 5 (PDE-5) Sildenafil Tadalafil Vardenafil
English: Of these 692 patients, 613 (300 atazanavir/cobicistat and 313 atazanavir/ritonavir) and 496 (250 atazanavir/cobicistat and 246 atazanavir/ritonavir) received at least 48 and 144 weeks of treatment, respectively.
Maltese: Minn dawn is-692 pazjent, 613 (300 atazanavir/cobicistat u 313 atazanavir/ritonavir) u 496 (250 atazanavir/cobicistat u 246 atazanavir/ritonavir) irċivew mill-inqas 48 u 144 ġimgħa ta' kura, rispettivament.
English: PDE-5 inhibitors are primarily metabolised by CYP3A.
Maltese: Impedituri ta' PDE-5 huma primarjament metabolizzati minn CYP3A.
English: SEDATIVES/HYPNOTICS Buspirone
Maltese: SEDATTIVI/MEDIĊINI IPNOTIĊI Buspirone
English: • protein in the urine (proteinuria)
Maltese: • proteina fl-awrina (proteinurja)
English: Tybost contains the active substance cobicistat.
Maltese: Tybost fih is-sustanza attiva cobicistat.
English: Cobicistat is not expected to induce CYP3A4 or P-gp (MDR1).
Maltese: Cobicistat mhux mistenni li jinduċi CYP3A4 jew P-gp (MDR1).
English: Table 4: Pharmacokinetic parameters [mean ± SD (%CV)] of atazanavir in the pharmacokinetic sub-study of phase 3 Study GS-US-216-0114
Maltese: Tabella 4: Parametri farmakokinetiċi [medja ± SD (%CV)] ta' atazanavir fis-sottostudju farmakokinetiku tal-Istudju ta' fażi 3 GS-US-216-0114
English: All corticosteroids excluding cutaneous products Corticosteroids primarily metabolised by CYP3A (including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone).
Maltese: Il-kortikosterojdi kollha minbarra prodotti għall-ġilda Kortikosterojdi primarjament metabolizzati minn CYP3A (inklużi betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone).
English: Pharmacotherapeutic group: All other therapeutic products, ATC code: V03AX03
Maltese: Il-prodotti terapewtiċi l-oħrajn kollha, Kodiċi ATC: V03AX03
English: Darunavir 800 mg + ritonavir 100 mg once daily (n = 31)
Maltese: Darunavir 800 mg + ritonavir 100 mg darba kuljum (n = 31)
English: Cmin: ↑ 66% Naloxone:
Maltese: Cmin: ↑ 66%
English: Each tablet contains 59 micrograms sunset yellow FCF aluminium lake (E110).
Maltese: Kull pillola fiha 59 mikrogramma ta' sunset yellow FCF aluminium lake (E110).
English: EU/1/13/872/001 30 film-coated tablets EU/1/13/872/002 90 (3 bottles of 30) film-coated tablets
Maltese: EU/1/13/872/002 90 (3 fliexken ta' 30) pillola miksija b'rita
English: Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (frequency cannot be estimated from the available data).
Maltese: Il-frekwenzi huma deskritti bħala komuni ħafna (≥ 1/10), komuni (≥ 1/100 sa < 1/10), mhux komuni (≥ 1/1,000 sa < 1/100), rari (≥ 1/10,000 sa < 1/1,000), rari ħafna (< 1/10,000), u mhux magħruf (frekwenza ma tistax tiġi stmata mid-data disponibbli).
English: [Outer packaging only]
Maltese: [Pakkett ta' barra biss]
English: ANTIARRHYTHMICS Disopyramide Flecainide
Maltese: MEDIĊINI ANTIARRITMIĊI Disopyramide
English: Darunavir 800 mg + cobicistat 150 mg once daily (n = 31)
Maltese: Darunavir 800 mg + cobicistat 150 mg darba kuljum (n = 31)
English: Cmax (µg/ml)
Maltese: AUCtau (µg•h/mL) Cmax (µg/mL) C0h (µg/mL)
English: ANTI-GOUT Colchicine
Maltese: MEDIĊINI KONTRA L-GOTTA Colchicine
English: Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1.
Maltese: Bil-kontra ta' ritonavir, cobicistat mhuwiex induttur ta' CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 jew UGT1A1.
English: insomnia, abnormal dreams
Maltese: insonnja, ħolm anormali
English: Atazanavir 300 mg once daily Darunavir 800 mg once daily
Maltese: Atazanavir 300 mg darba kuljum Darunavir 800 mg darba kuljum
English: See sections 4.4, 4.8 and 5.2.
Maltese: Ara sezzjonijiet 4.4, 4.8 u 5
English: In Study GS-US-216-0114, hyperbilirubinaemia (> 1 x ULN) was common: 97.7% in the cobicistatboosted atazanavir plus emtricitabine and tenofovir disoproxil fumarate fixed-dose combination group, and 97.4% in the ritonavir-boosted atazanavir plus emtricitabine and tenofovir disoproxil fumarate fixed-dose combination group through 144 weeks of treatment.
Maltese: Fl-Istudju GS-US-216-0114, iperbilirubinimja (> 1 x ULN) kienet komuni: 97.7% fil-grupp ta' kombinazzjoni ta' doża fissa ta' atazanavir imsaħħaħ minn cobicistat u emtricitabine u tenofovir disoproxil fumarate u 97.4% fil-grupp ta' kombinazzjoni ta' doża fissa ta' atazanavir imsaħħaħ minn ritonavir u emtricitabine u tenofovir disoproxil fumarate sal-144 ġimgħa ta' kura.
English: Digoxin (0.5 mg single dose)/Cobicistat (150 mg multiple doses)
Maltese: Digoxin (0.5 mg doża waħda)/Cobicistat (150 mg dożi multipli)
English: • buspirone, clorazepate, diazepam, estazolam, flurazepam, perphenazine, risperidone,
Maltese: • buspirone, clorazepate, diazepam, estazolam, flurazepam, perphenazine, risperidone, thioridazine, zolpidem, mediċini li jintużaw għat-trattament ta' disturbi tas-sistema nervuża
English: Cobicistat is not expected to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2C19.
Maltese: Cobicistat mhux mistenni li jinibixxi CYP1A2, CYP2B6, CYP2C8, CYP2C9 jew CYP2C19.
English: How to take Tybost
Maltese: Doża ta' Tybost
English: • sedatives/hypnotics: orally administered midazolam, triazolam
Maltese: • mediċini sedattivi/ipnotiċi: midazolam li jingħata mill-ħalq, triazolam
English: In the ritonavir group, genotypic data was available for all 19 virologic failures.
Maltese: Fil-grupp ta' ritonavir, dejta ġenotipika kienet disponibbli għad-19-il falliment viroloġiku kollha.
English: Following oral administration of [14C]cobicistat, 86% and 8.2% of the dose were recovered in faeces and urine, respectively.
Maltese: Wara l-għoti mill-ħalq ta' [14C]cobicistat, 86% u 8.2% tad-doża ġiet irkuprata fl-ippurgar u fl-awrina, rispettivament.
English: e.g., withdrew consent, loss to follow-up.
Maltese: effikaċja, eż., irtiraw il-kunsens, nuqqas ta' follow-up.
English: • Tybost must be taken with atazanavir (300 mg) or darunavir (800 mg).
Maltese: • Tybost irid jittieħed ma' atazanavir (300 mg) jew darunavir (800 mg).
English: Atazanavir pharmacokinetics parameters
Maltese: Parametri farmakokinetiċi ta' atazanavir
English: Co-administration of cobicistat with medicinal products such as dihydroergotamine, ergotamine, ergometrine, orally administered midazolam, triazolam, amiodarone, quinidine, pimozide, lurasidone, alfuzosin, simvastatin, lovastatin, and sildenafil which are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated (see section 4.3).
Maltese: L-għoti ta' cobicistat flimkien ma' prodotti mediċinali bħal dihydroergotamine, ergotamine, ergometrine, midazolam mogħti oralment, triazolam, amiodarone, quinidine, pimozide, lurasidone, alfuzosin, simvastatin, lovastatin, u sildenafil li huma dipendenti ħafna fuq CYP3A għat-tneħħija u li għalihom konċentrazzjonijiet għoljin fil-plażma huma assoċjati ma' avvenimenti serji u/jew ta' periklu għall-ħajja hu kontraindikat (ara sezzjoni 4.3).
English: • clarithromycin and rifabutin, medicines used to treat bacterial infections including tuberculosis
Maltese: • clarithromycin u rifabutin, mediċini li jintużaw għal trattament ta' infezzjonijiet batteriċi li jinkludu t-tuberkulosi
English: Co-administration with dabigatran etexilate, a P-glycoprotein (P-gp) substrate, is contraindicated (see section 4.5).
Maltese: L-għoti flimkien ma' dabigatran etexilate, substrat ta' glikoproteina P (P-gp - P-glycoprotein), huwa kontraindikat (ara sezzjoni 4.5).
English: Week 144
Maltese: Ġimgħa 144
English: Tybost is used in adults aged 18 years and over who are infected with HIV, the virus that causes acquired immunodeficiency syndrome (AIDS).
Maltese: Tybost jintuża f'adulti minn età ta' 18-il sena u aktar li huma infettati bl-HIV, il-virus li jikkawża ssindrome tal-immunodefiċjenza akkwiżita (AIDS).
English: Among the 21 patients, 3 developed the emtricitabine-associated resistance substitution M184V.
Maltese: Fost il-21 pazjent, 3 żviluppaw is-sostituzzjoni ta' reżistenza M184V assoċjata ma' emtricitabine.
English: Tybost contains the azo colouring agent sunset yellow FCF (E110), which may cause allergic reactions.
Maltese: Tybost fih is-sustanza koloranti azo sunset yellow FCF (E110), li tista' tikkawża reazzjonijiet allerġiċi.
English: No clinically relevant pharmacokinetic differences due to ethnicity have been identified for cobicistat.
Maltese: Etniċità L-ebda differenza farmakokinetika klinikament rilevanti minħabba l-etniċità ma ġiet identifikata għal cobicistat.
English: An increase of > 3 x ULN in alanine aminotransferase or aspartate aminotransferase was recorded in 12.8% of subjects in the cobicistatboosted group and 9.0% in the ritonavir-boosted group.
Maltese: Żieda ta' > 3 x ULN f'alanine aminotransferase jew aspartate aminotransferase ġiet osservata fi 12.8% tal-individwi fil-grupp imsaħħaħ minn cobicistat u fi 9.0% fil-grupp imsaħħaħ minn ritonavir.
English: Dose of HIV-1 protease inhibitor
Maltese: Doża tal-inibitur tal-protease ta' HIV-1
English: Darunavir pharmacokinetics parameters
Maltese: Parametri farmakokinetiċi ta' darunavir
English: • metformin, medicine used for the treatment of type 2 diabetes
Maltese: • metformin, mediċina li tintuża għal trattament ta' dijabete ta' tip 2
English: Median baseline CD4+ cell count (range), cells/mm3
Maltese: Medjan fil-linja bażi tal-għadd ta' ċelluli CD4+ (medda), ċellula/mm3
English: The safety of Tybost in 73 HIV-1 infected treatment-experienced patients with mild to moderate renal impairment (eGFR by Cockcroft-Gault method 50-89 ml/min) who switched pharmacokinetic enhancer from ritonavir to cobicistat was evaluated in an open-label clinical Study (GS-US-236-0118) of cobicistat-boosted atazanavir or darunavir plus two NRTIs.
Maltese: Is-sigurtà ta' Tybost fi 73 pazjent infettati bl-HIV-1 li ngħataw kura fil-passat li kellhom indeboliment renali ħafif sa moderat (eGFR ta' 50-89 mL/min bil-metodu ta' Cockcroft-Gault) li qalbu enhancer farmakokinetiku minn ritonavir għal cobicistat ġiet evalwata fl-Istudju kliniku open-label (GS-US-236-0118) ta' atazanavir imsaħħaħ minn cobicistat jew darunavir imsaħħaħ minn cobicistat flimkien ma' żewġ NRTIs.
English: Virologic success
Maltese: Suċċess viroloġiku
English: How to store Tybost
Maltese: Tiħux Tybost
English: • amlodipine, digoxin, diltiazem, disopyramide, felodipine, flecainide, lidocaine, metoprolol,
Maltese: • amlodipine, digoxin, diltiazem, disopyramide, felodipine, flecainide, lidocaine, metoprolol, mexiletine, nicardipine, nifedipine, propafenone, timolol u verapamil, mediċini li jintużaw għat-trattament ta' problemi tal-qalb
English: AUCtau (µg•h/ml) Cmax (µg/ml) Ctau (µg/ml) a Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination
Maltese: AUCtau (µg•h/mL) Cmax (µg/mL) Ctau (µg/mL) a Flimkien ma' kors fl-isfond ta' kombinazzjoni ta' doża fissa emtricitabine 200 mg u tenofovir disoproxil fumarate 300 mg
English: Some examples include, but are not limited to, itraconazole, ketoconazole, and voriconazole (see Table 2).
Maltese: Xi eżempji jinkludu, iżda mhumiex limitati għal, itraconazole, ketoconazole, u voriconazole (ara Tabella 2).
English: The effect of cobicistat on atazanavir pharmacokinetics was demonstrated in the pharmacokinetic substudy (n = 48) of the phase 3 Study GS-US-216-0114 in which HIV-1 infected patients received atazanavir 300 mg + cobicistat 150 mg or atazanavir 300 mg + ritonavir 100 mg, both in combination with emtricitabine and tenofovir disoproxil fumarate fixed-dose combination.
Maltese: L-effett ta' cobicistat fuq il-farmakokinetika ta' atazanavir intwera fis-sottostudju farmakokinetiku (n = 48) tal-Istudju ta' fażi 3 GS-US-216-0114 li fih pazjenti infettati bl-HIV-1 irċievew atazanavir 300 mg + cobicistat 150 mg jew atazanavir 300 mg + ritonavir 100 mg, it-tnejn flimkien ma' kombinazzjoni ta' doża fissa ta' emtricitabine u tenofovir disoproxil fumarate.
English: Other types of medicine: • ketoconazole, itraconazole, voriconazole, posaconazole and fluconazole, medicines used to treat fungal infections
Maltese: • ketoconazole, itraconazole, voriconazole, posaconazole u fluconazole, mediċini li jintużaw għal trattament ta' infezzjonijiet fungali